Prostate Cancer Trials

Phase 3 Clinical Trial in 1st-line Castrate-Resistant Prostate Cancer (CRPC)

The SYNERGY Clinical Trial is a Phase 3 study designed to evaluate the ability of custirsen to improve survival when added to the first-line standard of care, docetaxel treatment. Patients will be randomly selected to receive the standard of care, with or without custirsen therapy.

The study will enroll approximately 1000 men with castrate-resistant prostate cancer (CRPC) and is being conducted in approximately 123 cancer centers throughout North America and Europe.

To learn more about the SYNERGY trial, click here.

Phase 3 Clinical Trial in 2nd-line Castrate-Resistant Prostate Cancer (CRPC)

The AFFINITY Clinical Trial is a Phase 3 study that will evaluate if custirsen when combined with the 2^nd-line chemotherapy, cabazitaxel, has the potential to improve survival outcomes for prostate cancer patients who have progressed following treatment with docetaxel. Patients will be randomly selected to receive cabazitaxel/prednisone with or without custirsen therapy.

The study will enroll approximately 630 men with castrate-resistant prostate cancer (CRPC) and is being conducted throughout North America, Europe, Russia and Australia.

To learn more about the AFFINITY trial, click here

Phase 2 Clinical Trial in Castrate-Resistant Prostate Cancer (CRPC)

The Pacific study aims to evaluate the potential benefit of adding OGX-427 to treatment for patients with CRPC. This study will enroll patients who are being treated with Zytiga and have evidence of a rising PSA but no evidence of symptomatic or radiographic progression. The study is designed to measure the treatment’s impact on disease progression and other endpoints, such as PSA and circulating tumor cells.

To learn more about the Pacific Study, click here.